Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Wenying Deng,Zeyi Zhao,Tao Zou,Tongdong Kuang,Jing Wang
DOI: https://doi.org/10.2147/dmso.s421527
2024-01-24
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Wenying Deng, 1, &ast Zeyi Zhao, 1, &ast Tao Zou, 2 Tongdong Kuang, 3, &ast Jing Wang 1, &ast 1 School of Basic Medical Sciences, University of South China, Hengyang, Hunan Province, 421001, People's Republic of China; 2 Department of Cardiovascular Medicine, First Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, People's Republic of China; 3 Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, Guangxi Province, 541199, People's Republic of China &astThese authors contributed equally to this workThese authors contributed equally to this study Correspondence: Tongdong Kuang, Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, 541199, People's Republic of China, Email Jing Wang, School of Basic Medical Sciences, University of South China, Hengyang, Hunan Province, 421001, People's Republic of China, Tel +86 15200735915, Email Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs for diabetes therapeutics. Hence, we conducted a comprehensive review of published literature on diabetic fusion protein-based drugs for diabetes, with a primary focus on immunoglobulin G (IgG) fragment crystallizable (Fc) region, albumin, and transferrin (TF). This review aims to provide a reference for the subsequent development and clinical application of fusion protein-based drugs in diabetes therapeutics. Keywords: diabetes mellitus, fusion protein, Fc protein, glucagon-like peptide 1 receptor agonists, transferrin, albumin Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated glucose in the blood levels (hyperglycemia). Prolonged metabolic disorders can result in systemic damage to various organs including the kidneys, eyes, heart, blood vessels and nerves, leading to chronic progressive lesions, hypofunction, and organ failure. 1–3 According to the 10th edition of the IDF diabetes atlas released by the International Diabetes Federation (IDF), the global number of people with DM is as high as 537 million, and its prevalence is increasing annually. 4 Type 1 diabetes mellitus (T1DM) is characterized by the autoimmune-mediated destruction of pancreatic β-cells, resulting in an absolute lack of insulin secretion and is most commonly diagnosed in children and adolescents. 4,5 Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and a relative lack of insulin secretion, which can cause by various etiologies. T2DM constitutes over 90% of clinical cases and is predominantly observed in middle-aged and elderly individuals. 6 Currently, the management of diabetes mellitus is based on a globally accepted "five-pronged" approach, encompassing health education, diet control, physical exercise, self-monitoring, and pharmacological intervention. The global market value of diabetes therapeutics drug accounted to 317.9 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4% from 2021 to 2030. 7 Fusion protein-based drugs are favored in the market among various diabetes medications due to their extended half-life and stability, which also indicates an increasing market demand with the rise of chronic diseases. 8 Genetic engineering technology allows for the development of fusion protein-based drugs that combine a functional target protein with a long half-life human-derived IgG Fc protein, albumin, or transferrin. Firstly, this fusion reduces the immunogenicity of the drug in vivo due to the human origin of the partner fusion protein. Secondly, the large relative molecular mass of the partner fusion protein, along with its unique ultra-long-acting mechanism, it reduces the kidney clearance of the target protein while preserving its original function, therefore extending the duration of drug effect. Currently, the majority of papers primarily focus on a holistic approach to long-acting proteins, however, they failed to provide a detailed analysis of the target and clinical dosing of fusion protein-based drugs in the field of diabetes drug therapy. Hence, we conducted a systemati -Abstract Truncated-
endocrinology & metabolism